GBT
Global Blood Therapeutics, Inc.
$68.49
Earnings Summary
Revenue | $14.12Mn |
Net Profits | $-73.03Mn |
Net Profit Margins | -517.25% |
Highlights
Global Blood Therapeutics, Inc.’s revenue jumped +Inf% since last year same period to $14.12Mn in the Q1 2020. On a quarterly growth basis, Global Blood Therapeutics, Inc. has generated 569.73% jump in its revenue since last 3-months.
Global Blood Therapeutics, Inc.’s net profit fell -49.27% since last year same period to $-73.03Mn in the Q1 2020. On a quarterly growth basis, Global Blood Therapeutics, Inc. has generated 23.91% jump in its net profits since last 3-months.
Global Blood Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -517.25% in the Q1 2020. On a quarterly growth basis, Global Blood Therapeutics, Inc. has generated 88.64% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Global Blood Therapeutics, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | -1.18 |
EPS Estimate Current Year | -1.18 |
Highlights
Global Blood Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.18 - a 9.23% jump from last quarter’s estimates.
Global Blood Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.18.
Key Ratios
Key ratios of the Global Blood Therapeutics, Inc. post its Q1 2022 earnings
Earning Per Share (EPS) | -1.26 |
Return on Assets (ROA) | -0.25 |
Return on Equity (ROE) | -1.49 |
Highlights
Global Blood Therapeutics, Inc.’s earning per share (EPS) fell -4.13% since last year same period to -1.26 in the Q1 2022. This indicates that the Global Blood Therapeutics, Inc. has generated -4.13% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Global Blood Therapeutics, Inc.’s return on assets (ROA) stands at -0.25.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Global Blood Therapeutics, Inc.’s return on equity (ROE) stands at -1.49.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-04 | -1.3 | -1.26 | 3.08% |
Company Information
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
Organisation | Global Blood Therapeutics, Inc. |
CEO | Ted Love |
